Escent Institute of Pharmaceutical Sciences and Research, Imphal, 795140, Manipur, India.
Department of Pharmaceutical Sciences, Faculty of Science and Engineering, Dibrugarh University, Dibrugarh, 786004, Assam, India.
Chem Biodivers. 2024 Jan;21(1):e202301299. doi: 10.1002/cbdv.202301299. Epub 2023 Dec 4.
Allium hookeri (F: Liliaceae), an indigenous plant of Manipur, India, is traditionally used to treat various diseases and disorders like diabetes, hypertension, and stomach ache. In our previous study, the methanol extract of the plant showed significant antidiabetic potential in rats. In the present study, we evaluated the antidiabetic potential of a flavonoid compound named MEA isolated from the methanolic leaf extract of A. Hookeri in rats. Additionally, we assessed the compound's mode of action through the molecular docking study. The MEA reduced the blood glucose level from 317±12.8 to 99.4±6.67 mg/dl after 21 days of treatment. Besides, MEA also restored the body weights and other biochemical parameters including lipid profile significantly compared to the diabetic group (p<0.001). The histoarchitecture of the pancreatic tissues of the MEA treated group was also improved compared to the diabetic group. In the docking study, the compound showed good binding affinity in the active binding site of the two structures of pancreatic beta-cell SUR1 (Sulfonylurea Receptor 1) subunit with CDocker energy -31.556 kcal/mol and -39.703 kcal/mol, respectively. The compound MEA was found to be drug-like with non-carcinogenic, non-mutagenic and non-irritant properties. These findings indicate the antidiabetic potential of MEA, which might act by modulating the pancreatic beta-cell SUR1 subunit present in the K channel. Hence, the MEA would be a promising lead molecule to develop new antidiabetic drug candidates of the future.
印度曼尼普尔邦的土生土长植物钩状葱(F:百合科),传统上用于治疗各种疾病和失调,如糖尿病、高血压和胃痛。在我们之前的研究中,该植物的甲醇提取物在大鼠中显示出显著的抗糖尿病潜力。在本研究中,我们评估了从 A. Hookeri 甲醇叶提取物中分离得到的一种名为 MEA 的类黄酮化合物在大鼠中的抗糖尿病潜力。此外,我们通过分子对接研究评估了该化合物的作用模式。MEA 治疗 21 天后,可将血糖水平从 317±12.8 降至 99.4±6.67mg/dl。此外,MEA 还显著恢复了体重和其他生化参数,包括脂质谱,与糖尿病组相比(p<0.001)。与糖尿病组相比,MEA 治疗组的胰腺组织组织学结构也得到了改善。在对接研究中,该化合物在两种胰腺β细胞 SUR1(磺酰脲受体 1)亚基结构的活性结合位点中表现出良好的结合亲和力,与 CDocker 能量分别为-31.556 kcal/mol 和-39.703 kcal/mol。该化合物 MEA 被发现具有类药性,无致癌性、非突变性和非刺激性。这些发现表明 MEA 具有抗糖尿病潜力,其作用可能是通过调节存在于 K 通道中的胰腺β细胞 SUR1 亚基。因此,MEA 将成为开发未来新型抗糖尿病药物候选物的有前途的先导分子。